Consensus $6.97. Cuts FY24 cash flow view to $9B from at least $10.5B. The company said, “The Company revised its full-year 2024 GAAP diluted EPS, Adjusted EPS and cash flow from operations guidance to reflect continued pressure in the Health Care Benefits segment, partially offset by strong performance in the Health Services and Pharmacy & Consumer Wellness segments.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- CVS HEALTH CORPORATION REPORTS SECOND QUARTER 2024 RESULTS AND REVISES FULL-YEAR 2024 GUIDANCE
- Options Volatility and Implied Earnings Moves This Week, August 05 – August 09, 2024
- CVS Earnings this Week: How Will it Perform?
- Phathom Pharmaceuticals announces VOQUEZNA added to CVS Caremark formularies
- CVS Health call volume above normal and directionally bullish
Questions or Comments about the article? Write to editor@tipranks.com